Archives — Current Month (13)
Biopharma Agrees to $215 Million Acquisition Deal (11/21/2018)
An H.C. Wainwright & Co. report detailed the terms of the definitive agreement concerning the merger.
Biopharma to Accelerate Trial Timeline with Amendment (11/21/2018)
The change relates to the onset of dosing for patients with different degrees of disease.
Biotech Ramps Up Philippine Sales of Livestock Feed Premix (11/21/2018)
A distributor of the proprietary product places a third large order.
Life Science Company Addresses Antibiotic Resistance Problem (11/18/2018)
This firm's proprietary technology provides an alternative to antibiotic use in livestock production.
Biotech Files Patent Application for Nitric Oxide Delivery Device (11/16/2018)
With this development, the company advances blood/plasma transfusion technology.
Imprimis: Priming the Pumps for a Big 2019 (11/15/2018)
Daniel Carlson of Tailwinds Research profiles a biotech company he is bullish on.
Catalysts Approaching for U.S. Developer of Cancer Therapeutics (11/10/2018)
An H.C. Wainwright & Co. report highlighted this biotech's upcoming key events to watch.
Biotech Announces Preclinical Data on its Intravaginal Rings at Meeting (11/10/2018)
A ROTH Capital Partners report relayed the contents of both presented abstracts.
Target Price Raised on Biotech in Anticipation of Clinical Trial Presentation (11/07/2018)
An H.C. Wainwright & Co. report discussed what investors might expect to hear from the company regarding its cholesterol-lowering therapy.
Coverage Initiated on Developer of Targeted Gene Therapies for Cancer (11/07/2018)
A LifeSci Capital report highlighted the advantages of this biotech story's lead candidate targeting bladder cancer.
Selectively Targeting Alzheimer's Disease's Root Cause Is Key, Biotech Says (11/07/2018)
This firm explains how its 15 years in drug development led to and supports this conclusion.
Hemp Sales Grow at CV Sciences: Q3 Beats Estimates, 2019 Outlook (11/07/2018)
Fincom Investment Partners takes a look at Q3 earnings for a U.S.-based CBD company and explains why it believes it offers good value.
A Canadian Cannabis Company for the Next Wave (11/06/2018)
Ron Struthers, who believes the ideal marijuana stock to buy at this time is one that is focused on cannabis oil, profiles one such company that he sees as undervalued.
More Archives
2018Oct Sep Aug Jul Jun May Apr Mar Feb Jan
2017Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2016Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2015Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
